US drug industry spies opportunities amid Japan's regulatory improvements
This article was originally published in SRA
Executive Summary
The US pharmaceutical industry association PhRMA has described as 'remarkable' the continuing improvements in the performance of Japan's regulatory agency, the PMDA, but still would like to see further progress in drug pricing and other reforms.